Home
Clinical Resources Search
PQI: Estrogen Receptor 1 (ESR1) Mutation Testing in Metastatic, Hormone-Receptor Positive, Human Epidermal Growth Factor Receptor 2-negative Breast Cancer

Estrogen Receptor 1 (ESR1) Mutation Testing in Metastatic, Hormone-Receptor Positive, Human Epidermal Growth Factor Receptor 2-negative Breast Cancer

Download PQI pdf 0.25MB

Last Updated: December 4, 2024

By: Irene Kang, MD

About this PQI

This PQI will outline the applicability, process, and importance of ESR1 mutation testing in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative (HR+HER2-) metastatic breast cancer.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Breast Cancer Genomics Guardant360

PQI

Frequently Searched

Supported by

Estrogen Receptor 1 (ESR1) Mutation Testing in Metastatic, Hormone-Receptor Positive, Human Epidermal Growth Factor Receptor 2-negative Breast Cancer

About this PQI

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Revumenib (Revuforj) for the Management of Acute Leukemia

PQI: Talectrectinib (Ibtrozi) for the Management of ROS1+ Advanced NSCLC

PQI: Zanidatamab-hrii (Ziihera) for the Management of Biliary Tract Cancer

PQI: Prophylaxis and Management of Skin Toxicities with Amivantamab (Rybrevant) and Lazertinib (Lazcluze) Treatment: The COCOON Protocol

PQI in Action: Abiraterone acetate (Yonsa®) Patient Selection and Management

PQI in Action: Enfortumab Vedotin-ejfv (Padcev®) and Pembrolizumab (Keytruda®) Management for Advanced or Metastatic Urothelial Carcinoma

PQI in Action: Fruquintinib (Fruzaqla®)

PQI in Action: Management of Tucatinib (Tukysa®) and Trastuzumab in HER2-Positive Metastatic Colorectal Cancer – 2

S9 E2: Love Languages in Cancer Care

S9 E1: Head & Neck Cancer Care: Clinical Progress & Compassionate Practice

S8 Bonus Eps 2: Inside ASCO 2025

S8 E15: Supporting Survivors at Work

Readiness Tracker

Treatment Support Kit: Elranatamab

Treatment Support Kit: Mirdametinib

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

PQI: Tucatinib (Tukysa®) Management

PQI: The Role of Pharmacy in Equitable Breast Cancer Care

PQI: Stomatitis Prophylaxis During Everolimus (Afinitor®) Therapy

PQI: Overview of Breast Cancer Survivorship

PQI in Action: Larotrectinib (Vitrakvi®) Overview

PQI: Selpercatinib (Retevmo®) Genomic Testing Management

PQI Podcast S6 Ep 2: Molecular Testing & Targeted Treatment in Colorectal Cancer

PQI Podcast S6 Ep 9: ctDNA Testing in GI Cancers

PQI: Sotorasib (Lumakras®) for KRAS G12C-mutated Non-Small Cell Lung Cancer (NSCLC)

PQI: Sotorasib (Lumakras®) Companion Diagnostics (QIAGEN therascreen® KRAS RGQ PCR Kit and Guardant360® CDx)

PQI in Action: Abiraterone acetate (Yonsa®) Patient Selection and Management

PQI in Action: Enfortumab Vedotin-ejfv (Padcev®) and Pembrolizumab (Keytruda®) Management for Advanced or Metastatic Urothelial Carcinoma

S9 E2: Love Languages in Cancer Care

PQI: Revumenib (Revuforj) for the Management of Acute Leukemia